Waiting times between examinations with intravascularly administered contrast media: a review of contrast media pharmacokinetics and updated ESUR Contrast Media Safety Committee guidelines.
Contrast media
Hepatic insufficiency
Pharmacokinetics
Practice guideline
Renal insufficiency
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
19
03
2023
accepted:
07
07
2023
revised:
04
06
2023
pubmed:
12
10
2023
medline:
12
10
2023
entrez:
12
10
2023
Statut:
ppublish
Résumé
The pharmacokinetics of contrast media (CM) will determine how long safe waiting intervals between successive CT or MRI examinations should be. The Contrast Media Safety Committee has reviewed the data on pharmacokinetics of contrast media to suggest safe waiting intervals between successive contrast-enhanced imaging studies in relation to the renal function of the patient. CLINICAL RELEVANCE STATEMENT: Consider a waiting time between elective contrast-enhanced CT and (coronary) angiography with successive iodine-based contrast media administrations in patients with normal renal function (eGFR > 60 mL/min/1.73 m
Identifiants
pubmed: 37823923
doi: 10.1007/s00330-023-10085-5
pii: 10.1007/s00330-023-10085-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2512-2523Informations de copyright
© 2023. The Author(s).
Références
Kwon C, Kang KM, Choi YH et al (2021) Renal safety of repeated intravascular administrations of iodinated or gadolinium-based contrast media within a short interval. Korean J Radiol 22:1547–1554
pubmed: 34132080
pmcid: 8390825
Bourin M, Jolliet P, Ballereau F (1997) An overview of the clinical pharmacokinetics of X-ray contrast media. Clin Pharmacokin 32:180–193
Dean PB, Kivisaari L, Kormano M (1983) Contrast enhancement pharmacokinetics of six ionic and nonionic contrast media. Invest Radiol 18:368–374
pubmed: 6618828
Bourrinet P, Dencausse A, Cochet P, Bromet-Petit M, Chambon C (1994) Whole body quantitative autoradiographic study of the biodistribution of iobitridol in rats. Invest Radiol 29:1057–1060
pubmed: 7721547
Coveney JR, Robbins MS (1989) Biodistribution and excretion of 125I ioversol in conscious dogs. Invest Radiol 24(Suppl 1):S23–S27
pubmed: 2592170
Dencausse A, Violas X, Feldman H, Havard P, Chambon C (1996) Pharmacokinetic profile of iobitridol. Acta Radiol Suppl 400:25–34
pubmed: 8619349
Gardeur D, Lautrou J, Millard JC, Berger N, Metzger J (1980) Pharmacokinetics of contrast media: experimental results in dog and man with CT implications. J Comput Assist Tomogr 4:178–185
pubmed: 7365016
Heglund IF, Michelet AA, Blazak WF, Furuhama K, Holtz E (1995) Preclinical pharmacokinetics and general toxicology of iodixanol. Acta Radiol Suppl 399:69–82
pubmed: 8610532
Lorusso V, Luzzani F, Bertani F, Tirone P, de Haën C (1994) Pharmacokinetics and tissue distribution of iomeprol in animals. Eur J Radiol 18(Suppl 1):S13–S20
pubmed: 8020515
Morin JP, Boutelet I, Toutain H, Fillastre JP (1988) Pharmacokinetics and renal accumulation of three iodinated contrast agents. A comparative study of Telebrix, Hexabrix and Omnipaque in the rabbit. Drugs Exp Clin Res 14:679–686
pubmed: 3246213
Mützel W, Speck U (1980) Pharmacokinetics and biotransformation of iohexol in the rat and the dog. Acta Radiol Suppl 362:87–92
pubmed: 6267898
Mützel W, Speck U, Weinmann HJ (1983) Pharmacokinetics of iopromide in rat and dog. Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd 118:85–90
pubmed: 6139085
Edelson J, Shaw D, Palace G (1984) Pharmacokinetics of iohexol, a new nonionic radiocontrast agent, in humans. J Pharm Sci 73(7):993–995
pubmed: 6470969
Fountaine H, Harnish P, Andrew E, Grynne B (1996) Safety, tolerance, and pharmacokinetics of iodixanol injection, a nonionic, iso-osmolar, hexa-iodinated contrast agent. Acad Radiol 3(Suppl 3):S475–S484
pubmed: 8883524
Krause W, Schuhmann-Giampieri G, Staks T, Kaufmann J (1994) Dose proportionality of iopromide pharmacokinetics and tolerability after i.v. injection in healthy volunteers. Eur J Clin Pharmacol 46:339–343
pubmed: 7957519
Lorusso V, Taroni P, Alvino S, Spinazzi A (2001) Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis. Invest Radiol 36:309–316
pubmed: 11410750
McKinstry DN, Rommel AJ, Sugerman AA (1984) Pharmacokinetics, metabolism, and excretion of iopamidol in healthy subjects. Invest Radiol 19(Suppl 5):S171–S174
Olsson B, Aulie A, Sveen K, Andrew E (1983) Human pharmacokinetics of iohexol. A new nonionic contrast medium. Invest Radiol 18:177–182
pubmed: 6408018
Spencer CM, Goa KL (1996) Iodixanol: a review of its pharmacodynamic and pharmacokinetic properties and diagnostic use as an X-ray contrast medium. Drugs 52:899–927
pubmed: 8957160
Svaland MG, Haider T, Langseth-Manrique K, Andrew E, Hals PA (1992) Human pharmacokinetics of iodixanol. Invest Radiol 27:130–133
pubmed: 1601604
Wilkins RA, Whittington JR, Brigden GS, Lahiri A, Heber ME, Hughes LO (1989) Safety and pharmacokinetics of ioversol in healthy volunteers. Invest Radiol 24:781–788
pubmed: 2793391
Hartwig P, Mützel W, Tänzer V (1989) Pharmacokinetics of iohexol, iopamidol, iopromide, and iosimide compared with meglumine diatrizoate. Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd 128:220–223
pubmed: 2568800
DiFazio LT, Singhvi SM, Heald AF et al (1978) Pharmacokinetics of iodamide in normal subjects and in patients with renal impairment. J Clin Pharmacol 18:35–41
pubmed: 338644
Feldman S, Hayman LA, Hulse M (1984) Pharmacokinetics of low- and high-dose intravenous diatrizoate contrast media administration. Invest Radiol 19:54–57
pubmed: 6706519
Corradi A, Menta R, Cambi V, Maccarini P, Cerutti R (1990) Pharmacokinetics of iopamidol in adults with renal failure. Arzneimittelforschung 40:830–832
pubmed: 2222559
Nossen JO, Jakobsen JA, Kjaersgaard P, Andrew E, Jacobsen PB, Berg KJ (1995) Elimination of the non-ionic X-ray contrast media iodixanol and iohexol in patients with severely impaired renal function. Scand J Clin Lab Invest 55:341–350
pubmed: 7569737
Allard M, Doucet D, Kien P, Bonnemain B, Caillé JM (1988) Experimental study of DOTA-gadolinium. Pharmacokinetics and pharmacologic properties. Invest Radiol 23(Suppl 1):S271–S274
pubmed: 3198361
Harpur ES, Worah D, Hals PA, Holtz E, Furuhama K, Nomura H (1993) Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 28(Suppl 1):S28–S43
pubmed: 8486501
Lorusso V, Arbughi T, Tirone P, de Haën C (1999) Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance). J Comput Assist Tomogr 23(Suppl 1):S181–S189
pubmed: 10608414
Robic C, Port M, Rousseaux O et al (2019) Physicochemical and pharmacokinetic profiles of gadopiclenol: a new macrocyclic gadolinium chelate with high T1 relaxivity. Invest Radiol 54:475–484
pubmed: 30973459
pmcid: 6661244
Tombach B, Heindel W (2002) Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol 12:1550–1556
pubmed: 12042967
Tweedle MF, Eaton SM, Eckelman WC et al (1988) Comparative chemical structure and pharmacokinetics of MRI contrast agents. Invest Radiol 23(Suppl 1):S236–S239
pubmed: 3198352
Vittadini G, Felder E, Tirone P, Lorusso V (1988) B-19036, a potential new hepatobiliary contrast agent for MR proton imaging. Invest Radiol 23(Suppl 1):S246–S248
pubmed: 3198355
Vogler H, Platzek J, Schuhmann-Giampieri G et al (1995) Preclinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. Eur J Radiol 21:1–10
pubmed: 8654452
Michel A, Bonnet PA, Fernandez JP, Chambon C, Doucet D (1992) Pharmacokinetic study of gadolinium-DOTA in control and streptozocin diabetic rats. J Pharm Pharmacol 44:902–906
pubmed: 1361534
Schuhmann-Giampieri G, Mahler M, Röll G, Maibauer R, Schmitz S (1997) Pharmacokinetics of the liver-specific contrast agent Gd-EOB-DTPA in relation to contrast-enhanced liver imaging in humans. J Clin Pharmacol 37:587–596
pubmed: 9243351
Frenzel T, Ulbrich HF, Pietsch H (2021) The macrocyclic gadolinium-based contrast agents gadobutrol and gadoteridol show similar elimination kinetics from the brain after repeated intravenous injections in rabbits. Invest Radiol 56:341–347
pubmed: 33259443
De Haën C, Lorusso V, Luzzani F, Tirone P (1995) Hepatic transport of the magnetic resonance imaging contrast agent gadobenate dimeglumine in the rat. Acad Radiol 2:232–238
pubmed: 9419554
Mühler A, Heinzelmann I, Weinmann HJ (1994) Elimination of gadolinium-ethoxybenzyl-DTPA in a rat model of severely impaired liver and kidney excretory function. An experimental study in rats. Invest Radiol 29:213–216
pubmed: 8169100
Mühler A, Weinmann HJ (1995) Biodistribution and excretion of
pubmed: 9419568
Hao J, Bourrinet P, Desché P (2019) Assessment of pharmacokinetic, pharmacodynamic profile, and tolerance of gadopiclenol, a new high relaxivity GBCA, in healthy subjects and patients with brain lesions (phase I/IIa study). Invest Radiol 54:396–402
pubmed: 30870257
Le Mignon MM, Chambon C, Warrington S et al (1990) Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers. Invest Radiol 25:933–937
pubmed: 2394577
McLachlan SJ, Eaton S, De Simone DN (1992) Pharmacokinetic behaviour of gadoteridol injection. Invest Radiol 27(Suppl 1):S12–S15
pubmed: 1506147
Staks T, Schuhmann-Giampieri G, Frenzel T et al (1994) Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol 29:709–715
pubmed: 7960618
Van Wagoner M, O’Toole M, Worah D, Leese PT, Quay SC (1991) A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. Invest Radiol 26:980–986
Van Wagoner M, Worah D (1993) Gadodiamide injection: first human experience with the nonionic magnetic resonance imaging enhancement agent. Invest Radiol 28(Suppl 1):S44–S48
pubmed: 8486503
Weinmann HJ, Laniado M, Mützel W (1984) Pharmacokinetics of GdDTPA/ dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 16:167–172
pubmed: 6505043
Gschwend S, Ebert W, Schultze-Mosgau M, Breuer J (2011) Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol 46:556–566
pubmed: 21623212
Hamm B, Staks T, Mühler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792
pubmed: 7754011
Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U (1992) Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 183:59–64
pubmed: 1549695
Spinazzi A, Lorusso V, Pirovano G, Kirchin M (1999) Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 6:282–291
pubmed: 10228617
Bradu A, Penescu M, Pitrou C et al (2021) Pharmacokinetics, dialysability and safety of gadopiclenol, a new gadolinium-based contrast agent, in patients with impaired renal function. Invest Radiol 56:486–493
pubmed: 34197356
Chachuat A, Molinier P, Bonnemain B et al (1992) Pharmacokinetics and tolerance of Gd-DOTA (DOTAREM) in healthy volunteers and in patients with chronic renal failure. Eur Radiol 2:326–329
Joffe P, Thomsen HS, Meusel M (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5:491–502
pubmed: 9653466
Reinton V, Berg KJ, Svaland MG et al (1994) Pharmacokinetics of gadodiamide injection in patients with moderately impaired renal function. Acad Radiol 1(Suppl 1):S56–S61
Schuhmann-Giampieri G, Krestin G (1991) Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 26:975–979
pubmed: 1743921
Swan SK, Lambrecht LJ, Townsend R et al (1999) Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 34:443–448
pubmed: 10399633
Tombach B, Bremer C, Reimer P et al (2000) Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Invest Radiol 35:35–40
pubmed: 10639034
Tombach B, Bremer C, Reimer P et al (2001) Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology 218:651–657
pubmed: 11230635
Yoshikawa K, Davies A (1997) Safety of ProHance in special populations. Eur Radiol 7(Suppl 5):S246–S250
Davies BE, Kirchin MA, Bensel K et al (2002) Pharmacokinetics and safety of gadobenate dimeglumine (MultiHance) in subjects with impaired liver function. Invest Radiol 37:299–308
pubmed: 11979156
Wedeking P, Tweedle MF (1988) Comparison of the biodistribution of
pubmed: 3255735
Wedeking P, Eaton S, Covell DG, Nair S, Tweedle MF, Eckelman WC (1990) Pharmacokinetic analysis of blood distribution of intravenously administered
pubmed: 2082126
Lancelot E (2016) Revisiting the pharmacokinetic profiles of gadolinium-based contrast agents: differences in long-term biodistribution and excretion. Invest Radiol 51:691–700
pubmed: 27175546
Bloem JL, Wondergem J (1989) Gd-DTPA as a contrast agent in CT. Radiology 171:578–579
pubmed: 2704827
Engelbrecht V, Koch JA, Rassek M, Mödder U (1996) Gadodiamide and gadolinium-DTPA as intravenous media in computed tomography. Fortschr Geb Rontgenstrahlen Nuklearmed 165:24–28
Gierada DS, Bae KT (1999) Gadolinium as a CT contrast agent: assessment in a porcine model. Radiology 210:829–834
pubmed: 10207488
Kim MD, Kim H (2003) Gadolinium dimeglumine as a contrast agent for digital subtraction angiography: in vitro Hounsfield unit measurement and clinical efficacy. Yonsei Med J 44:138–142
pubmed: 12619187
Quinn AD, O’Hare NJ, Wallis FJ, Wilson GF (1994) Gd-DTPA: an alternative contrast medium for CT. J Comput Assist Tomogr 18:634–636
pubmed: 8040451
Schmitz SA, Wagner S, Schuhmann-Giampieri G, Wolf KJ (1995) Evaluation of gadobutrol in a rabbit model as a new lanthanide contrast agent for computed tomography. Invest Radiol 30:644–649
pubmed: 8557505
Schmitz SA, Wagner S, Schuhmann-Giampieri G, Krause W, Bollow M, Wolf KJ (1997) Gd-EOB-DTPA and Yb-EOB-DTPA: two prototypic contrast media for CT detection of liver lesions in dogs. Radiology 205:361–366
pubmed: 9356615
Zwicker C, Langer M, Langer R, Keske U (1991) Comparison of iodinated and noniodinated contrast media in computed tomography. Invest Radiol 26(Suppl 1):S162–S164 (discussion S165-S166)
pubmed: 1808117
Nyman U, Elmståhl B, Leander P, Nilsson M, Golman K, Almén T (2002) Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia? Radiology 223:311–318 (discussion 328-329)
pubmed: 11997530
Nyman U, Elmståhl B, Geijer H, Leander P, Almén T, Nilsson M (2011) Iodine contrast iso-attenuating with diagnostic gadolinium doses in CTA and angiography results in ultra-low iodine doses. A way to avoid both CIN and NSF in azotemic patients? Eur Radiol 21:326–336
pubmed: 20803203
Kaufman JA, Geller SC, Waltman AC (1996) Renal insufficiency: gadopentetate dimeglumine as a radiographic contrast agent during peripheral vascular interventional procedures. Radiology 198:579–581
pubmed: 8596869
Spinosa DJ, Angle JF, Hartwell GD, Hagspiel KD, Leung DA, Matsumoto AH (2002) Gadolinium-based contrast agents in angiography and interventional radiology. Radiol Clin North Am 40:693–710
pubmed: 12171180
Strunk HM, Schild H (2004) Actual clinical use of gadolinium-chelates for non-MRI applications. Eur Radiol 14:1055–1062
pubmed: 14872279
Elmståhl B (2006) Are gadolinium contrast media really less nephrotoxic than iodine agents in radiographic examinations? A comparison in relation to their ability to attenuate X-rays in a pig model. Lund University Faculty of Medicine: Doctoral Dissertation Series 2006:9
Thomsen HS, Almèn T, Morcos SK, Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR) (2002) Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 12:2600–2605
pubmed: 12271402
Andreisek G, Froehlich JM, Hodler J et al (2008) Direct MR arthrography at 1.5 and 3.0 T: signal dependence on gadolinium and iodine concentrations–phantom study. Radiology 247:706–716
pubmed: 18403628
Choi JY, Kang HS, Hong SH et al (2008) Optimization of the contrast mixture ratio for simultaneous direct MR and CT arthrography: an in vitro study. Korean J Radiol 9:520–525
pubmed: 19039268
pmcid: 2627248
Ganguly A, Gold GE, Butts Pauly K et al (2007) Quantitative evaluation of the relaxivity effects of iodine on GD-DTPA enhanced MR arthrography. J Magn Reson Imaging 25:1219–1225
pubmed: 17520728
Kopka L, Funke M, Fischer U, Vosshenrich R, Schröder M, Grabbe E (1994) Signal characteristics of X-ray contrast media and their interaction with gadolinium-DTPA in MRI. Fortschr Geb Rontgenstrahlen Nuklearmed 160:349–352
Montgomery DD, Morrison WB, Schweitzer ME, Weishaupt D, Dougherty L (2002) Effects of iodinated contrast and field strength on gadolinium enhancement: implications for direct MR arthrography. J Magn Reson Imaging 15:334–343
pubmed: 11891980
Hergan K, Doringer W, Längle M, Oser W (1995) Effects of iodinated contrast agents in MR imaging. Eur J Radiol 21:11–17
pubmed: 8654453
Jinkins JR, Robinson JW, Sisk L, Fullerton GD, Williams RF (1992) Proton relaxation enhancement associated with iodinated contrast agents in MR imaging of the CNS. AJNR Am J Neuroradiol 13:19–27
pubmed: 1595441
pmcid: 8331758
Morales H, Lemen L, Samaratunga R, Nguyen P, Tomsick T (2016) Effects of iodinated contrast on various magnetic resonance imaging sequences and field strength: implications for characterization of hemorrhagic transformation in acute stroke therapy. World J Radiol 8:588–593
pubmed: 27358686
pmcid: 4919758
Di Gregorio E, Arena F, Gianolio E, Ferrauto G, Aime S (2022) The interaction between iodinated X-ray contrast agents and macrocyclic GBCAs provides a signal enhancement in T1-weighted MR images: insights into the renal excretion pathways of Gd-HPDO3A and iodixanol in healthy mice. Magn Reson Med 88:357–364
pubmed: 35253921
pmcid: 9314041
Ogura A, Hayakawa K, Miyati T, Maeda F (2009) Effects of iodinated contrast agent on diffusion weighted magnetic resonance imaging. Acad Radiol 16:1196–1200
pubmed: 19541508
Wang JH, Ren K, Sun WG, Zhao L, Zhong HS, Xu K (2014) Effects of iodinated contrast agents on renal oxygenation level determined by blood oxygenation level dependent magnetic resonance imaging in rabbit models of type 1 and type 2 diabetic nephropathy. BMC Nephrol 15:140
pubmed: 25182068
pmcid: 4236662
European Society of Urogenital Radiology Contrast Media Safety Committee. ESUR Guidelines on contrast safety, v10, 2018. Available at: https://www.esur.org/esur-guidelines-on-contrast-agents/ . Accessed 27 May 2023